Press Releases

WASHINGTON, Sept. 12, 2019 /PRNewswire/ -- International Leaders Summit (ILS), a US-based think tank, will host the inaugural US-India Leaders Summit at The National Press Club in Washington, DC on September 18, 2019, to advance policies addressing healthcare, trade and security. Speakers include Dr.

SAN DIEGO, Sep. 12, 2019 /PRNewswire/ -- NI Research is pleased to announce that the September/October issue of NeuroPerspective has been released. It features our&nbs

ROANOKE, Va., Sept. 12, 2019 /PRNewswire/ -- Hollins Communications Research Institute (HCRI), a national center for stuttering research and therapy innovation, just completed another research initiative in collaboration with the National Institutes of Health (NIH). The study is the first to evaluate stuttering therapy outcomes among a group of stutterers who possess on

KELOWNA, BC, Sept. 12, 2019 /PRNewswire/ - Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF) (the "Company" or "Valens"), a vertically integrated provider of industry leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analy

NEW YORK and SHANGHAI, Sept.12, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engage

CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment

Trait Acquires Exclusive License to Apply These New Technologies to Cannabis, Hemp LOS ALAMOS, N.M., Sept. 12, 2019 /PRNewswire/ -- Trait Biosciences Inc. ("Trait"

TAMPA, Florida, Sept. 12, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, announced today that it notified FDA that it was commencing enrollment in its first-i

WESTON, Fla., Sept. 12, 2019 /PRNewswire/ -- ZyVersa Therapeutics, Inc., (ZyVersa) a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that the August 15th edition of BIOCENTURY Innovations reported ZyVersa's perspecti

KIRKLAND, Wash., Sept. 12, 2019 /PRNewswire/ -- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the publication of the REDUCE FMR clinical study of its Carillon Mitral Contour System®. The Carillon®&nbs